Community-acquired pneumonia (CAP) remains a significant cause of global mortality. Clinicians often face uncertainty when deciding on the role of corticosteroids in pneumonia management. While these drugs can modulate harmful systemic inflammation, past clinical trials produced conflicting results regarding their efficacy. However, recent evidence suggests that inflammatory biomarkers, particularly C-reactive protein (CRP), can help personalize this therapy for better patient outcomes.

The 200 mg/L CRP Threshold

Recent high-quality meta-analyses have clarified which patients benefit most from steroid therapy. Specifically, researchers found that high CRP concentrations at admission identify a hyperinflammatory state. Consequently, studies show that patients with CRP levels exceeding 200 mg/L (specifically 204 mg/L in large-scale trials) experience a significant reduction in 30-day mortality when receiving corticosteroids. Furthermore, these patients show lower rates of treatment failure compared to those with lower inflammatory markers. Moreover, administering steroids to patients with low CRP levels might offer no survival benefit while increasing the risk of adverse effects.

Implementing Corticosteroids in Pneumonia Management

Current clinical guidelines now reflect these findings. For instance, the 2024 Society of Critical Care Medicine (SCCM) update strongly recommends systemic corticosteroids for hospitalized patients with severe CAP. Similarly, the 2025 American Thoracic Society (ATS) guidelines suggest steroids for severe cases to reduce mortality. Therefore, physicians should prioritize early CRP testing to identify candidates for this intervention. Additionally, clinicians must monitor for complications such as hyperglycemia and potential hospital readmission. Ultimately, tailoring therapy to the patient\'s inflammatory subphenotype ensures that steroids provide maximal benefit without unnecessary risk.

Frequently Asked Questions

What is the recommended CRP level for starting steroids in CAP?

Evidence from recent data-driven analyses suggests that a CRP threshold of 204 mg/L is a reliable indicator of potential mortality benefit from adjunctive corticosteroid therapy.

Should steroids be used in viral pneumonia like influenza?

No, most evidence indicates that corticosteroids may be harmful or offer no benefit in patients with influenza pneumonia, unlike their clear benefit in severe bacterial CAP or COVID-19.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Soriano Puig A et al. Biomarker-guided use of corticosteroids in pneumonia. Pneumonia (Nathan). 2026 undefined undefined. doi: 4. PMID: 41736159.


2. Smit JM et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med. 2025;13(3):221-233. doi:10.1016/S2213-2600(24)00405-3.


3. Chaudhuri D et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med. 2024 May;52(5):e219-e233.